Manhattan Research Releases New Research on DTC's Impact on Pharma Website Visitation

Manhattan ResearchNuvaRing® and Latisse® are the top pharmaceutical brands in terms of having the highest percentage of overall product website traffic driven by their DTC television advertisements, according to pharmaceutical and healthcare market research company Manhattan Research. The findings are from ePharma Consumer® v9.0, the company's newly released study focused on the attitudes and behaviors of consumers researching prescription drug information online. NuvaRing®, a contraceptive manufactured by Merck, jumped five spots from last year to take the top ranking.

Latisse®, an eyelash enhancement treatment launched last year by Allergan, was also successful in driving individuals online for additional information.

Top Pharma Product Sites in Terms of Percentage of Traffic Driven by DTC Television Ads

1. NuvaRing®
2. Latisse®
3. Cialis®
4. Boniva®
5. Abilify®
6. Gardasil®
7. Yaz®
8. Viagra®
9. Levitra®
10. Lunesta™

Among consumers online for pharma information and sites for which n>60

"In today's multi-channel world, marketing initiatives must be designed to work together for optimal results," says Meredith Ressi, Vice President of Research at Manhattan Research. "While the television ad is critical to building awareness, for many patients, the Internet is a next stop for learning more before going on to speak to their physician about a product."

Mrs. Ressi will discuss these findings and more during a complimentary webinar to be held on Thursday, January 21st at 11:00 AM, EST.

Complimentary Pharma eMarketing Webinar - Thursday, January 21, 2010

Manhattan Research Vice President of Research Meredith Ressi will preview the latest trends in how consumers research and interact with online prescription drug information from the ePharma Consumer® study. Key topics include:

  • Which brands (250+ tracked) are the most successful in driving consumers online and satisfying them with engaging content? How does your brand measure up to the competition?
  • What roles do search, social media, and online video play in the ePharma landscape?
  • What are some of the general attitudes and future interests of consumers seeking prescription drug information online?
ePharma Consumer® v9.0: Online Pharmaceutical Information-Seeking Landscape

Thursday, January 21, 11:00 AM EST

Register here: https://www2.gotomeeting.com/register/491612787

About ePharma Consumer® v9.0
ePharma Consumer® v9.0 is focused on the attitudes and behaviors of consumers seeking pharmaceutical information online. The study was conducted via online survey in Q4 2009 among 6,575 adults (age 18+). ePharma Consumer® also provides data on more than 250 pharmaceutical product websites. Clients can segment the broad market research to provide in-depth data on more than 85 condition groups. For additional product and subscription information, please visit http://www.manhattanresearch.com/epc.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...